Zevalin® First Line in Follicular Lymphoma
NCT00772655
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Follicular Lymphoma
Interventions
DRUG:
90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab
DRUG:
Rituximab
Sponsor
Charite University, Berlin, Germany